Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Finished Goods: 2017-2019

Historic Finished Goods for Ironwood Pharmaceuticals (IRWD) over the last 1 years, with Dec 2019 value amounting to $191,000.

  • Ironwood Pharmaceuticals' Finished Goods was N/A to $191,000 in Q4 2019 from the same period last year, while for Dec 2019 it was $191,000, marking a year-over-year change of. This contributed to the annual value of $191,000 for FY2019, which is N/A change from last year.
  • According to the latest figures from Q4 2019, Ironwood Pharmaceuticals' Finished Goods is $191,000, which was down 58.21% from $457,000 recorded in Q3 2019.
  • Over the past 5 years, Ironwood Pharmaceuticals' Finished Goods peaked at $1.4 million during Q1 2018, and registered a low of $76,000 during Q3 2018.
  • Its 3-year average for Finished Goods is $589,429, with a median of $479,000 in 2017.
  • Its Finished Goods has fluctuated over the past 5 years, first tumbled by 84.13% in 2018, then skyrocketed by 501.32% in 2019.
  • Quarterly analysis of 3 years shows Ironwood Pharmaceuticals' Finished Goods stood at $735,000 in 2017, then slumped by 84.13% to $76,000 in 2018, then soared by 501.32% to $191,000 in 2019.
  • Its last three reported values are $191,000 in Q4 2019, $457,000 for Q3 2019, and $76,000 during Q3 2018.